Answers are grounded in this paper and cite their sources.
Case report reveals relapsing Guillain–Barré syndrome linked to autoimmune disease and cancer, suggesting tailored treatment approaches.
Guillain–Barré syndrome (GBS) is an acute immune-mediated peripheral neuropathy typically characterized by a monophasic course; however, atypical or relapsing presentations suggest that sustained immune dysregulation contribute to disease heterogeneity. We report a 33-year-old man with progressive limb weakness diagnosed as motor-predominant acute inflammatory demyelinating polyradiculoneuropathy (AIDP), supported by albuminocytologic dissociation and demyelinating features on nerve conduction studies with preserved sensory conduction. Immunological evaluation revealed B lymphocyte expansion, elevated interleukin-6 and interleukin-8 levels, and strong thyroid autoantibody positivity consistent with Graves’ disease, while anti-ganglioside and paraneoplastic antibodies were negative. The clinical course was marked by immune-triggered relapses and the patient responded well to intravenous immunoglobulin (IVIg) and FcRn inhibition with efgartigimod. Further investigation identified papillary thyroid carcinoma harboring a BRAF V600E mutation, after which neurological symptoms stabilized following thyroidectomy. This case illustrates a rare concurrence of relapsing AIDP, Graves’ disease, and papillary thyroid carcinoma, and supports the hypothesis that persistent systemic immune activation underlies relapsing GBS, rather than a chronic demyelinating process. Clinically, it highlights the importance of considering underlying autoimmune and neoplastic conditions in atypical or relapsing GBS to guide individualized management.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: